STUDY00015328: Sepsis Endotypes

Part of paid clinical trials in Hershey, Pennsylvania.

Sponsor
Milton S. Hershey Medical Center
Study ID
NCT03146546
Status
Enrolling By Invitation

Conditions

  • Sepsis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. We hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.

Key Dates

Start date
Aug 6, 2020
Status verified
Sep 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Sepsis
    Patients with sepsis as defined by the Sepsis-3 criteria
  • Arm: Control
    Patients without sepsis, as defined by the Sepsis-3 criteria

Primary Outcome Measure

death and chronic critical illness [ Time Frame: 5 years for completion of study, 1 year follow up per patient enrolled ]

Locations (1)

FacilityCityStateZIPSite coordinators
Milton S. Hershey Medical CenterHersheyPennsylvania17033-

Find similar trials in Hershey, PA

By research site
Milton S. Hershey Medical Center· Hershey, PA

Related Studies